News | May 01, 2025
Sigachi Industries signs MoU with Respilon Group
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
ekincare has raised a total funding of $22M since 2015 till date
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Subscribe To Our Newsletter & Stay Updated
